Xconomy
OCTOBER 7, 2016
—Alnylam Pharmaceuticals (NASDAQ: ALNY ) of Cambridge, MA, said that it would shelve its drug revusiran after 18 patients died in a Phase 3 study to treat the rare disease transthyretin amyloidosis. —Merrimack Pharmaceuticals (NASDAQ: MACK ) announced layoffs of 22 percent of its staff and the resignation of CEO Robert Mulroy.
Xconomy
NOVEMBER 4, 2019
An experimental Halozyme Therapeutics treatment for pancreatic cancer has failed a pivotal study, and the company is stopping further development of the drug and closing its oncology operations as part of a corporate restructuring.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Xconomy
JULY 15, 2016
After last week’s revelation of three patient deaths in its leading cancer immunotherapy trial, the FDA suspended the study. CEO Jeff Jonas told Xconomy previously that positive results could encourage Sage to dive deeper into studying mood disorders—from panic attacks to post-traumatic stress disorder.
Xconomy
JUNE 17, 2016
. —All the while, Merck (NYSE: MRK ) disclosed pembrolizumab (Keytruda) bested chemotherapy in a Phase 3 trial of previously untreated patients with non-small cell lung cancer; the study was stopped early because of the positive results.
Xconomy
JANUARY 25, 2019
In a week of big personnel moves, none was more surprising than Editas Medicine CEO Katrine Bosley’s departure.
Xconomy
JUNE 30, 2017
There is no Obamacare replacement, at least not as of this writing. The Senate Republicans are fractured, with a handful of conservatives and moderates each giving a cold shoulder to their chamber’s version of healthcare reform, the Better Care Reconciliation Act.
Xconomy
SEPTEMBER 15, 2017
It was a week of realignments. President Trump, who used to be known as “The Donald” but now goes by “ Amnesty Don ,” kept up the parlay-voo with his new friends Chuck and Nancy. Martin Shkreli, who was once known— and still is!
Expert insights. Personalized for you.
77 
Let's personalize your content